GlassScriptPhysician profile
Nicholas Joseph Guido
NPI 1558893529
$4,478.14
in general payments reported to CMS, 2019-2025
21 companies · $1,140 in 2025
The $1,140 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.72 · 2021: $285 · 2022: $222 · 2023: $1,331 · 2024: $1,482 · 2025: $1,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,755 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,755.07 |
| Education | $198.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $913.37 | 2021-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $706.67 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $632.30 | 2021-2024 | Arazlo, Siliq, Duobrii |
| Sun Pharmaceutical Industries INC. | $374.71 | 2022-2025 | Ilumya |
| Lilly USA, LLC | $277.41 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $275.04 | 2023-2025 | Opzelura |
| Ucb, INC. | $209.37 | 2021-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $209.08 | 2023-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $169.63 | 2023-2024 | |
| Mayne Pharma Commercial LLC | $162.13 | 2023 | |
| Leo Pharma INC. | $127.20 | 2023-2025 | Adbry, Spevigo |
| Novartis Pharmaceuticals Corporation | $87.00 | 2021-2025 | |
| Dermavant Sciences, INC. | $79.21 | 2023-2024 | Vtama |
| Organon LLC | $52.11 | 2025 | Vtama, Nexplanon |
| Galderma Laboratories, L.P. | $50.77 | 2025 | Aklief, Nemluvio |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $43.79 | 2024-2025 | Seysara |
| E.R. Squibb & Sons, L.L.C. | $41.76 | 2023 | Sotyktu |
| Genentech USA, INC. | $18.72 | 2020 | |
| Biofrontera INC. | $17.47 | 2024 | Rhodoled Xl, Ameluz, Xepi |
| Journey Medical Corporation | $15.48 | 2022 | |
| Amgen INC. | $14.92 | 2025 | Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Guido listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.